ArticleTargeted oncology2024

Taiwan Nationwide Study of First-Line ALK-TKI Therapy in ALK-Positive Lung Adenocarcinoma.

Zhe-Rong Zheng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.